AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04271709 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Intervention Using Patient Navigators
Description: Enhanced support includes patient navigators to assist with all aspects of follow-up eye care and ocular surgery at either Harkness Eye Institute or Harlem Hospital, specifically eye exam appointment scheduling and arranging transportation over a 1-year period.
Study NCT04271709 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual Care subjects who fail the screening and need vision correction will be given an eyeglasses prescription and a list of optical shops within 1 mile from their home. These subjects who are referred to an ophthalmologist for a follow-up eye exam will only be scheduled for their initial appointment at either Harkness Eye Institute or Harlem Hospital. They will not receive enhanced support. Scheduling this initial appointment will allow tracking of adherence.
Study NCT01828242 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowerment model to improve dietary intake
Description: Empowerment model using specific guidelines to improve dietary intake
Study NCT01828242 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group following conventional approach
Description: Control group following conventional approach
Study NCT01709019 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
Description: 0.5mL IM injections
Study NCT01709019 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28)
Description: 0.5mL IM injections
Study NCT01709019 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
Description: 0.5mL IM injections
Study NCT04748809 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet 1
Description: Dietary intervention
Study NCT04748809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet 2
Description: Dietary intervention
Study NCT02528630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive resistance strength training program
Description: Patients undergo to strength training for intrinsic muscles of the hand twice a week, during 12 weeks.
Study NCT02528630 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Joint protection and energy conservation advice
Description: A session regarding joint protection and energy conservation for hands was done before randomization.
Study NCT02528630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Joint protection and energy conservation advice
Description: A session regarding joint protection and energy conservation for hands was done before randomization.
Study NCT03680482 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention ingest a 48 mg of sucralose
Description: Intervention: Subjects with type 2 diabetes who ingest a 48 mg of sucralose. Sucralose is a non-caloric sweetener derived from sucrose and is 600 times more sweet than sucrose. Your allowable daily intake is 15 mg / kg of body weight per day. 85% is not absorbed and is excreted unchanged in the stool; the rest that is absorbed is excreted unchanged by the urine
Study NCT03680482 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention ingest a 96 mg of stevia
Description: Intervention: Subjects with type 2 diabetes who ingest a 96 mg of stevia (steviol glycosides). The word stevia refers to the whole plant of Stevia rebaudiana Bertoni (SRB), only some of the components of the stevia leaf are sweet. Steviol glycosides are up to 300 times sweeter than sucrose, do not provide calories and can be used as a substitute for sucrose or as a non-nutritive sweetener alternative. Your allowable daily intake is 4 mg / kg / body weight (expressed as steviol)
Study NCT00449930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: (1) sitagliptin 100mg tablet once daily (q.d.) for a 24-wk treatment period
Study NCT00449930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: metformin hydrochloride
Description: (4) Metformin 500mg tablets once daily (q.d.) for a 24-wk treatment period.
Study NCT04810507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anagliptin BID Treatment
Description: Continuous Glucose Monitoring with Anagliptin 100mg BID or Sitagliptin 100mg QD treatment for 12 weeks
Study NCT04810507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anagliptin BID Treatment
Description: Continuous Glucose Monitoring with Anagliptin 100mg BID or Sitagliptin 100mg QD treatment for 12 weeks
Study NCT01664000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioureidobutyronitrile
Description: Kevetrin (thioureidobutyronitrile)
Study NCT00367679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib is an oral, potent, multi-target receptor tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-alpha and -beta and c-kit. Subjects were to receive 800 mg oral pazopanib daily for a minimum of 2 weeks to a maximum of 6 weeks.
Study NCT03090919 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet transfusion
Study NCT03090919 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT03402620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins
Description: Human menopausal gonadotropin 75 IU ampoules start at cycle day 2
Study NCT01669668 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Description: Undergo RFA
Study NCT01669668 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopy
Description: Undergo laparoscopic ultrasound
Study NCT03620773 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aminohippurate Sodium Inj 20%
Description: Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
Study NCT01709019 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
Description: 0.5mL IM injections
Study NCT03620773 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Iohexol Inj 300 mg/mL
Description: Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
Study NCT03620773 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Vertical Sleeve Gastrectomy
Description: Participants will undergo vertical sleeve gastrectomy surgery, a laparoscopic bariatric surgery procedure designed for weight loss in obese patients
Study NCT03620773 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Renal Biopsy
Description: Minimally invasive outpatient procedure in interventional radiology to obtain renal tissue cores.
Study NCT01709019 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)
Description: 0.5mL IM Injections
Study NCT01480908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography at rest
Description: Dimensions of all 4 chambers, inspiratory collapse, and gradient over the tricuspid valve is measured. Tricuspid Annulus Plane Systolic Excursion(TAPSE) and Tricuspid Annular peak Systolic Motion(TASM) is measured as well.
Study NCT01480908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography during exercise
Description: TASM is measured during exercise along with pulse measurements to evaluate the force-frequency-relation.
Study NCT01480908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI at rest
Description: Dimensions of all 4 chambers are measured at end-systole and end-diastole. Blood flow measurements through the aortic and the pulmonary valve are made as well. No use of contrast.
Study NCT01480908 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise testing
Description: Maximal oxygen consumption is measured during on a bicycle. Prior to the test a spirometry is performed to rull out potential differences in pulmonary function between the cohorts. During the test pulse, blood pressure, saturation, and EKG are monitored. Ventilatory volume, oxygen consumption and carbon dioxide excretion are measured. Anaerobic threshold is calculated at the end of the test.
Study NCT01528631 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: D-Fagomine
Description: 30 mg (initial dose), with 50 grams of sucrose in 200 ml of water.
Study NCT01528631 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: D-Fagomine
Description: 0 mg (control) blended with 50 grams of sucrose in 200 ml of water.
Study NCT02965469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathe2Relax
Description: The app teaches diaphragmatic breathing and has audiovisual coaching
Study NCT02583178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aegis Sierra Ligation System
Description: The SLS is a series of devices designed for epicardial ligation of the left atrial appendage through a minimally invasive transcatheter approach.
Study NCT00366678 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Description: Single 0.5 mL dose given at 2, 3, 4, and 12 months of age.
Study NCT00366678 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7-valent pneumococcal conjugate vaccine
Description: Single 0.5 mL dose given at 2, 3, 4, and 12 months of age.
Study NCT00366678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentavac
Description: The Pentavac was administered by intramuscular injection 0.5 ml into the anterolateral thigh muscle of the right leg at 2, 3, and 4 months (infant series) and 12 months of age (toddler dose).
Study NCT00366678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentavac
Description: The Pentavac was administered by intramuscular injection 0.5 ml into the anterolateral thigh muscle of the right leg at 2, 3, and 4 months (infant series) and 12 months of age (toddler dose).
Study NCT02007369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WhatsApp
Description: Intervention arm with relapse prevention intervention in the social group via the social networking service WhatsApp and the duration of the intervention will be 8 weeks.
Study NCT02007369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facebook
Description: Another intervention arm with the same intervention content, but the platform for the participants to share and receive quitting advice is Facebook and the duration of the intervention will be 8 weeks.
Study NCT03151967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus crispatus CTV-05
Description: vaginal applicator with medium containing drug
Study NCT03151967 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vaginal applicator with medium containing no drug
Study NCT00470119 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: behavioral dietary intervention
Description: A group based modification of the DPP and LookAHEAD lifestyle programs with a goal of 10% weight loss
Study NCT00470119 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise intervention
Description: Facility based and home-based exercise designed to increase moderate-to-vigorous aerobic activity in participants to 45 mins/day 5 days/week
Study NCT03822936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Description: Preoperative chemotherapy, carbon ion therapy, surgery
Study NCT03822936 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Description: Preoperative chemotherapy, carbon ion therapy, surgery
Study NCT01190098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Subjects randomized to lacosamide according to the following schedule:~Treatment Phase Week Dose Week 1 LCM 50 mg bid Week 2 LCM 100 mg bid Week 3 LCM 150 mg bid Week 4 LCM 200 mg bid
Study NCT01190098 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be packaged identically to experimental drug and titrated according to the same schedule.
Study NCT02768220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: empagliflozin
Description: Test to see how 30 days of jardiance changes serum and urinary advanced glycation end product levels
Study NCT02768220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin
Description: Test to see how 30 days of tradjenta changes serum and urinary advanced glycation end product levels
Study NCT03798522 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral ultrasound guided erector spinae plane block
Description: ESPB on both sides at T7 before GA
Study NCT03798522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine
Description: in nalbuphine for analgesia after GA
Study NCT03125629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 FDG
Description: Radiolabel for positron emission tomography / computed tomography (PET/CT) and computed tomography (PET/CT) imaging
Study NCT03125629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68-DOTA-TATE
Description: Radiolabel for positron emission tomography / computed tomography (PET/CT) and computed tomography (PET/CT) imaging
Study NCT03125629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography / Computed Tomography (PET/CT) Scan
Description: Scan using a regular medical care (IDE-exempt) Discovery 600 / 690 PET/CT scanner.
Study NCT03125629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Scan
Description: Scan using a NOVEL GE PET/MRI scanner.
Study NCT01283711 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: apollo device
Description: RF treatments for wrinkles and rhytides reduction
Study NCT03066635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A 25 IU
Description: injection with 25 IU botulinum toxin towards the otic ganglion (symptomatic side) using image-guided navigation and the MultiGuide device
Study NCT03066635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A 12.5 IU
Description: injection with 12.5 IU botulinum toxin towards the otic ganglion (symptomatic side) using image-guided navigation and the MultiGuide device
Study NCT03829033 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy with either photons or protons.
Study NCT03829033 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy with either photons or protons.
Study NCT01476345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2963016
Description: Administered subcutaneously
Study NCT01476345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lantus
Description: Administered subcutaneously
Study NCT03552679 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiography
Study NCT00747422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera™ System
Description: ultrasound treatment
Study NCT02337426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl Fumarate
Description: Given PO
Study NCT02337426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT02337426 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT02537067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHONDRON
Description: 1. Harvesting of ankle or knee cartilage~2. The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue.
Study NCT03918395 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo beverage
Description: A placebo beverage will be consumed both post-exercise and pre-bed
Study NCT03918395 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein-polyphenol beverage
Description: A protein-polyphenol beverage will be consumed both post-exercise and pre-bed
Study NCT03707522 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Growth mindset
Description: 10 minute interactive article describing neuroplasticity
Study NCT01387087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT03707522 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modifiable risk factor (MRF) information
Description: 10 minute interactive article describing modifiable risk factors for depression and anxiety
Study NCT02610062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS67E
Description: Intravenous (IV) infusion
Study NCT03447769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: 200 mg of canakinumab administered subcutaneously on day 1 of every 21-day cycle for 18 cycles. Canakinumab solution for injection was provided by Novartis as ready-to-use pre-filled syringes to be administered by study personnel.
Study NCT03447769 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously on day 1 of every 21-day cycle for 18 cycles. Placebo solution for injection was provided by Novartis as ready-to-use pre-filled syringes to be administered by study personnel.
Study NCT04040985 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total Knee Arthroplasty using LEGION™ Total Knee System
Description: Primary Total Knee Arthroscopy using LEGION™ Total Knee System
Study NCT03707522 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 10 minute interactive article describing activity scheduling
Study NCT03707522 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: 10 minute interactive article describing activity scheduling
Study NCT01321749 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Description: The detail of RIPC included five cycles of bilateral upper limbs 5/5 min. of ischemia and reperfusion alternation. Limb ischemia was induced by inflating tourniquets to 200 mmHg. This process was placed on both arms every day.
Study NCT03481673 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPE for Asthma
Description: The intervention will consist of 7 weekly sessions (30 minutes each). COPE for Asthma is a manualized, cognitive behavior skills-building intervention to improve the physical and mental health outcomes of children with asthma and elevated symptoms of anxiety or depression.
Study NCT04445129 — intervention group
Intervention type: DEVICE
Intervention: Portable EEG Device
Description: Portable EEG device is lightweight and designed for nighttime wear.
Study NCT04445129 — intervention group
Intervention type: DEVICE
Intervention: Portable ECG Device
Description: Portable ECG device is waterproof and will be adhered to the chest of the participant.
Study NCT04445129 — intervention group
Intervention type: DEVICE
Intervention: Accelerometry
Description: Portable accelerometry device is noninvasive and will capture data on participant activity level, including intensity of movement, rest, and sleep.
Study NCT01660490 — intervention group
Intervention type: PROCEDURE
Intervention: ORIF
Description: Open reduction internal fixation of the proximal femur
Study NCT02535676 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: The device will produce a direct current of 2 mA from one electrode to the other. In active stimulation, the device will be turned on for 20 min and in sham stimulation the device will be turned in 2 mA for one minute and will be automatically turned off the remaining 19 minutes. The sham or active mode is chosen by a numeric code.
Study NCT02535676 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: The device will produce a direct current of 2 mA from one electrode to the other. In active stimulation, the device will be turned on for 20 min and in sham stimulation the device will be turned in 2 mA for one minute and will be automatically turned off the remaining 19 minutes. The sham or active mode is chosen by a numeric code.
Study NCT01900379 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Description: This device consists in a nasal continuous positive airway pressure. It will be applied just after CABG and for 3 months for OSA/CPAP patients group.
Study NCT01900379 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham CPAP treatment
Description: This device consists in a sham continuous positive airway pressure. It will be applied just after CABG and for 3 months for OSA/sham CPAP patients group.
Study NCT00990028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 20 mg oral, for 10 days
Study NCT00990028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 mg vehicle
Study NCT00175383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: luteinizing hormone-releasing hormone (LHRH) short acting or long acting
Description: See Detailed Description.